Related references
Note: Only part of the references are listed.Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
Hugo Larose et al.
HAEMATOLOGICA (2021)
miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma
Anna Garbin et al.
HAEMATOLOGICA (2021)
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2021)
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan
Hideto Iwafuchi et al.
HUMAN PATHOLOGY (2021)
Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent
Chuquan Shang et al.
CANCERS (2021)
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK plus ALCL
Zuoqiao Wu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1
Eric J. Lowe et al.
BLOOD (2021)
Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib
Chaowei Ren et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Hayato Mizuta et al.
NATURE COMMUNICATIONS (2021)
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Si-Min Qi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Shaowen Xie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile
Chaowei Ren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Synergistic Drug Combinations Prevent Resistance in ALK plus Anaplastic Large Cell Lymphoma
Giulia Arosio et al.
CANCERS (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
Deficiency of Wiskott-Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes
Seong-Su Han et al.
ONCOGENE (2021)
The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells
Xuejiao Zhou et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
Yanrong Li et al.
INVESTIGATIONAL NEW DRUGS (2020)
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms
Noriko Yanagitani et al.
CANCER SCIENCE (2020)
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
Ning Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Soumya S. Rajan et al.
ONCOGENE (2020)
ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation
Wenfeng Gou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
Nina Prokoph et al.
BLOOD (2020)
Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial
Reiji Fukano et al.
CANCER SCIENCE (2020)
PROTAC: A promising technology for cancer treatment
Xin Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
Domenico Sorrentino et al.
CANCERS (2020)
B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Zhenguo Zi et al.
CANCERS (2020)
STAT3 and p53: Dual Target for Cancer Therapy
Thu-Huyen Pham et al.
BIOMEDICINES (2020)
miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
Coralie Hoareau-Aveilla et al.
HAEMATOLOGICA (2019)
Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
Nicole Prutsch et al.
LEUKEMIA (2019)
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death
Avedis Torossian et al.
HAEMATOLOGICA (2019)
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Deepali Sawant et al.
NATURE IMMUNOLOGY (2019)
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
Bhawana George et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK plus ALCL
Rui Wu et al.
BLOOD (2019)
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
Matteo Menotti et al.
NATURE MEDICINE (2019)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
The broken cycle: E2F dysfunction in cancer
Lindsey N. Kent et al.
NATURE REVIEWS CANCER (2019)
Efficacy of nivolumab in a patientwith systemic refractory ALK plus anaplastic large cell lymphoma
Charlotte Rigaud et al.
PEDIATRIC BLOOD & CANCER (2018)
Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs
Kaijun Geng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase - Positive Anaplastic Large Cell Lymphoma
Wendan Xu et al.
CANCER RESEARCH AND TREATMENT (2018)
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Chung Hyo Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
Monica Ceccon et al.
CANCERS (2018)
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma
C. A. Murga-Zamalloa et al.
ONCOGENE (2017)
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
Jo-Anne van der Krogt et al.
HAEMATOLOGICA (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
Jo-Anne van der Krogt et al.
HAEMATOLOGICA (2017)
Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas
Coralie Hoareau-Aveilla et al.
CANCERS (2017)
ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
Christabel Wilson et al.
SCIENTIFIC REPORTS (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
M. Ceccon et al.
ONCOGENE (2016)
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
Aurelie Courtin et al.
BRITISH JOURNAL OF CANCER (2016)
Anaplastic large cell lymphoma in paediatric and young adult patients
Suzanne D. Turner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
ALK F1174V mutation confers sensitivity while ALK 11171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
Sai-Hong Ou et al.
LUNG CANCER (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli et al.
ONCOTARGET (2016)
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
Michela Boi et al.
ONCOTARGET (2016)
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
Melanie R. Hassler et al.
CELL REPORTS (2016)
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma
Chengsheng Wu et al.
BLOOD (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Novel ALK inhibitors in clinical use and development
Chaitanya Iragavarapu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2015)
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
Geraldine Mitou et al.
ONCOTARGET (2015)
Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
Apolinar Maya-Mendoza et al.
MOLECULAR ONCOLOGY (2015)
The importance of Notch signaling in peripheral T-cell lymphomas
Maria Rorbaek Kamstrup et al.
LEUKEMIA & LYMPHOMA (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Perilous journey: a tour of the ubiquitin-proteasome system
Gary Kleiger et al.
TRENDS IN CELL BIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma
Cuiling Liu et al.
BLOOD (2013)
Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma
Ju Gao et al.
BMC CANCER (2013)
Novel TRAF1-ALK Fusion Identified by Deep RNA Sequencing of Anaplastic Large Cell Lymphoma
Andrew L. Feldman et al.
GENES CHROMOSOMES & CANCER (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex
Rocco Piazza et al.
NEOPLASIA (2013)
MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
Deeksha Vishwamitra et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Teeara Berry et al.
CANCER CELL (2012)
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas
Daniela Laimer et al.
NATURE MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression
Cecile Desjobert et al.
BLOOD (2011)
Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA
M. Marzec et al.
ONCOGENE (2011)
IL-2R common γ-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK
Qian Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions
Samar A. Hegazy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
Megan S. Lim et al.
BLOOD (2009)
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
Ping Shi et al.
BLOOD (2009)
Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation
Christine Damm-Welk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches
Mariusz A. Wasik et al.
SEMINARS IN ONCOLOGY (2009)
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Khandaker Al Zaid Siddiquee et al.
CELL RESEARCH (2008)
γc-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes
Monika Kasprzycka et al.
JOURNAL OF IMMUNOLOGY (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
An oncogene-induced DNA damage model for cancer development
Thanos D. Halazonetis et al.
SCIENCE (2008)
Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma
Mariko Watanabe et al.
LABORATORY INVESTIGATION (2008)
STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression
Qian Zhang et al.
NATURE MEDICINE (2007)
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Philipp B. Staber et al.
BLOOD (2007)
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf
M. Marzec et al.
ONCOGENE (2007)
STAT1 as a key modulator of cell death
Hun Sik Kim et al.
CELLULAR SIGNALLING (2007)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Jirina Bartkova et al.
NATURE (2006)
Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation
Kwang Woon Kim et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
Monika Kasprzycka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy
S Pattingre et al.
CELL (2005)
Inhibition of Akt increases P27KiP1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
GZ Rassidakis et al.
BLOOD (2005)
NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner
A Slupianek et al.
EXPERIMENTAL HEMATOLOGY (2004)
Anaplastic lymphoma kinase proteins in growth control and cancer
K Pulford et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Share Paper
